# ANALYST INTERVIEW: ImmuPharma’s Lupuzor and long term potential – TLSD

- Link: https://www.directorstalkinterviews.com/analyst-interview-immupharmas-lupuzor-and-long-term-potential-tlsd/412792571
- Published: 2019-09-11T08:22:21+01:00
- Author: Giles Arbor

**ImmuPharma plc** (LON: IMM) is the topic of conversation when Navid Malik Executive
Director at The Life Sciences Division joins DirectorsTalk. Navid provides some 
background to TLSD and it’s interest in ImmuPharma, gives a summary of it’s new 
note on the company, provides some key points on the longer term potential of Lupuzor,
Lupus drugs in the market and key milestones he expects the company to achieve over
the next period of reach the target share price of 76p.

**About ImmuPharma plc**

ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the
London Stock Exchange focusing on developing novel medicines with high sales potential
in specialist markets with serious unmet need. ImmuPharma is led by a commercially
focused Board and management team with extensive experience.

**About Lupuzor™**

Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma’s lead compound
and a potential treatment for Lupus (or Systemic Lupus Erythematosus), a chronic,
potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism
of action aimed at modulating the body’s immune system so that it does not attack
healthy cells, and avoids causing adverse side effects. It has the potential to 
halt the progression of the disease in a substantial proportion of patients.

Share on:
